Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin-1 or interleukin-6 inhibition may be linked to high fatality lung disease in systemic juvenile idiopathic arthritis.
Doug Roberts, MD, discusses the effect that the novel coronavirus could have in patients who are immunocompromised with rheumatic diseases.
The European League Against Rheumatism developed recommendations for the collection, analysis, and use of big data in rheumatic and musculoskeletal disorders.
Patricia Cagnoli, MD, discusses the current gaps in lupus care and A Vision for Lupus initiative that aims to raise awareness and improve access to healthcare for patients with lupus.
Researchers measured discordance between patient or family and physician global activity scores in juvenile dermatomyositis, and determined factors associated with discordance.
Yusuf Yazici, MD, discussed the effect of the intra-articular inhibitor treatment, lorecivivint, on patient-reported outcomes in patients with knee osteoarthritis.
In this Q&A, Dr Jeffery R Curtis discusses the applications of the multibiomarker disease activity Vectra® test in measuring rheumatoid arthritis disease activity.
The 2019 update of the American College of Rheumatology recommendations on disease activity measurements in rheumatoid arthritis was recently released.
In a phase 3 study, researchers assessed the efficacy and safety of ixekizumab in patients with active nonradiographic axial spondyloarthritis.
The first report of the sessions and presentations scheduled to take place at the 2019 ACR/ARP Annual Meeting, being held November 8 to 13 in Atlanta, Georgia.
